Meeder Asset Management Inc Madrigal Pharmaceuticals, Inc. Transaction History

Meeder Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$171.37 - $283.23 $1,713 - $2,832	10 New	10 $2,000
Q3 2021 Nov 08, 2021	SELL	$78.35 - $105.02 $263,569 - $353,287	-3,364 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$97.2 - $137.59 $326,980 - $462,852	3,364 New	3,364 $328,000
Q1 2019 Apr 16, 2019	SELL	$103.48 - $143.84 $57,638 - $80,118	-557 Closed	0 $0
Q4 2018 Jan 17, 2019	SELL	$94.77 - $215.54 $473 - $1,077	-5 Reduced 0.89%	557 $63,000
Q3 2018 Nov 02, 2018	BUY	$207.3 - $300.31 $26,119 - $37,839	126 Added 28.9%	562 $0
Q2 2018 Jul 24, 2018	BUY	$101.55 - $313.9 $33,105 - $102,331	326 Added 296.36%	436 $0
Q1 2018 May 03, 2018	BUY	$93.35 - $149.04 $280 - $447	3 Added 2.8%	110 $13,000
Q4 2017 Feb 02, 2018	BUY	$39.35 - $97.37 $3,541 - $8,763	90 Added 529.41%	107 $10,000
Q3 2017 Oct 20, 2017	BUY	$15.48 - $46.19 $263 - $785	17	17 $1,000

298

22M

757K

370K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $3.63B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.